•Genetic BioTek, a US and China joint venture, aims to R&D, manufacture, and market ultra high sensitive, early detection kits for cancer gene mutations worldwide.
•Our products are based on pyrophosphorolysis activated polymerization (PAP), a next generation of nucleic acid amplification technology with a brand new principle.
•The consequent products have unique or much-better performance than PCR/RT-PCR based products, over 1,000 times more sensitive and selective.
•Our products include mutation detection kits of EGFR, KRAS, BRAF, NRAS, and EML4-ALK genes, as well as of personalized cancer signature mutations.
•The kits can be applied to 1) early screening and early diagnosis of cancer, 2) early monitoring of cancer relapse, 3) early discovering and monitoring of acquired drug resistance, and 4) selection of therapy.
•In addition, the kits are provided in freeze-dried format, much earlier and user-friendly manipulation.
•Our second next generation of technology is a new two-layer column that comprises two distinct membranes within the column for nucleic acid extraction.
•The resulting products are particularly suitable for isolating much diluted nucleic acid in large volumes, e.g., as large as 50ml of plasma and 200ml of urine, making better sample sources feasible for early detection of cancer.
Company’s Keywords:
cancer, pap, nucleic, rna, pcr, diagnosic, dna, rtpcr, hiv, liquid biospy, tumer, ivd
0
medical devices
2012
Your request has been submitted successfully.
Own or work here?